Match!
Francesco Montagnani
Academy for Urban School Leadership
CancerPathologyOncologyChemotherapyMedicine
34Publications
8H-index
388Citations
What is this?
Publications 35
Newest
#1Edoardo FranciniH-Index: 13
Last. Grace Shaw (Harvard University)H-Index: 3
view all 20 authors...
30Background: BM in patients (pts) with CRPC are associated with shorter overall survival (OS) and higher costs. BRI zoledronic acid and denosumab are frequently used to prevent skeletal-related ev...
Source
#1Lorenzo FornaroH-Index: 17
#2Francesco Leone (UNITO: University of Turin)H-Index: 20
Last. Francesco MontagnaniH-Index: 8
view all 25 authors...
ABSTRACT Background FOLFIRINOX is an option for fit patients with metastatic (MPC) and locally advanced unresectable (LAPC) pancreatic cancer. However, no criteria reliably identify patients with better outcome. Patients and Methods We investigated putative prognostic factors among 137 MPC/LAPC patients treated with triplet chemotherapy. Association with 6-month survival status (primary endpoint) was assessed by multivariate logistic regression models. A nomogram predicting the risk of death at ...
Source
#1Edoardo FranciniH-Index: 13
Last. Daniel Yick Chin Heng (U of C: University of Calgary)H-Index: 33
view all 20 authors...
e16508Background: BM in patients (pts) with CRPC correlate with higher mortality and costs. BRI zoledronic acid and denosumab are frequently used for the prevention of skeletal-related events (SRE)...
Source
Source
#1A. Casadei GardiniH-Index: 20
#2Marco PuzzoniH-Index: 7
Last. Mario ScartozziH-Index: 32
view all 12 authors...
1 CitationsSource
#1Cindy Neuzillet (Curie Institute)H-Index: 3
#2A. Casadei GardiniH-Index: 20
Last. David Propper (QMUL: Queen Mary University of London)H-Index: 23
view all 54 authors...
Abstract Background The benefit of second-line chemotherapy (L2) over standard first-line (L1) gemcitabine plus cisplatin (GEMCIS) or oxaliplatin (GEMOX) chemotherapy in advanced biliary tract cancer (aBTC) is unclear. Our aim was to identify and validate prognostic factors for overall survival (OS) with L2 in aBTC to guide clinical decisions in this setting. Methods We performed a retrospective analysis of four prospective patient cohorts: a development cohort (28 French centres) and three vali...
Source
#1Lorenzo FornaroH-Index: 17
#2Caterina VivaldiH-Index: 10
Last. Francesco MontagnaniH-Index: 8
view all 20 authors...
HER2 is the only validated predictive biomarker in gastro-oesophageal carcinoma (GOC). However, several factors, such as heterogeneity in protein expression, shortage of evaluable tumour tissue and need for quick target assessment, underline the usefulness of a pre-screening tool in order to anticipate HER2 status. Data from 723 consecutive GOC analysed for HER2 at four Italian Institutions were collected. HER2 positivity was defined as 3+ by immunohistochemistry (IHC) or 2+ with gene amplificat...
Source
Source
Abstract Background Despite the amelioration of systemic therapy, overall survival (OS) of metastatic gastric cancer (GC) patients remains poor. Liver is a common metastatic site and retrospective series suggest a potential OS benefit from hepatectomy, with interesting 5-year (5 y) and 10-year (10 y) OS rates in selected patients. We aim to evaluate the impact of liver resection and related prognostic factors on long-term outcome in this setting. Methods We searched Pubmed, EMBASE, and Abstracts...
1 CitationsSource
#1Lorenzo FornaroH-Index: 17
#2A ParnofielloH-Index: 1
Last. Francesco MontagnaniH-Index: 8
view all 20 authors...
Source
1234